The therapeutic potential of 161Tb has been explored in tumor-targeted radionuclide therapy, with recent clinical trials demonstrating its application in prostate-specific membrane antigen (PSMA)-targeted therapy. This evidence concerns the gene FOLH1 and neoplasm.